- Data illustrates potent neutralization activity against the Gamma and Delta Variants of SARS-CoV-2
- Receives EUR3 million grant to accelerate clinical development
- Exevir one step closer in development of ‘pan-coronavirus’ nanobodies
Belgium, July 13, 2021: ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has generated data on its COVID-19 antibody XVR011 which demonstrate in vitro neutralization activity against SARS-CoV-2 Variants of Concern Gamma and Delta. The company has also obtained grant funding of €3 million from the Flanders Agency for Innovation & Entrepreneurship (VLAIO) to accelerate clinical development of lead asset, the unique llama-derived VHH72-Fc antibody XVR011.